StockData

Niki BioSolutions, Inc. (NIKI) stock

NIKINasdaqMeasuring & Controlling Devices, NECFiscal year ends December 31
Số liệu tài chính tới Q4 năm tài chính 2025, quý kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 27, 2026Score 4/30
$1.60+0.10 (+6.67%)

Close on Nov 18, 2026Market cap $13.03MP/E –Yield –

Niki BioSolutions r&d expenses

Research and development expenses are spending on new products and technology.

Niki BioSolutions's R&D Expenses for the twelve months ending Dec 31, 2025 was $352.88K. For fiscal 2025 it was $352.88K, down 83.9% from the year before. The highest annual figure on record is $11.59M in fiscal 2020.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$352.88K-83.9%
FY2024Dec 31, 2024$2.20M-57.8%
FY2023Dec 31, 2023$5.20M-43.6%
FY2022Dec 31, 2022$9.22M-15.2%
FY2021Dec 31, 2021$10.87M-6.2%
FY2020Dec 31, 2020$11.59M+67.0%
FY2019Dec 31, 2019$6.94M+123.7%
FY2018Dec 31, 2018$3.10M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025$91.71K–
Q3 FY2025Sep 30, 2025$241.79K–
Q3 FY2024Sep 30, 2024$440.70K–

More Niki BioSolutions figures

See a number that looks wrong?